In Regulatory Notice 13-31, FINRA gave guidance regarding its
approach and expectations when it conducts a suitability
examination. FINRA's critical starting off point begins
with its analysis of firm controls through interviews with
principals responsible for preparing the firm's policies and
FINRA is providing this guidance as it has only been a little
more than a year since the new "suitability" rule took
effect. As part of the overall examination process, FINRA
will typically ask the following questions:
What training has the firm deployed regarding the change in
Does the firm offer training for associated persons to address
investment strategies and hold recommendations?
How are investment strategies (including hold recommendations)
defined and supervised?
What are the firm's supervisory and compliance procedures
for determining whether there was a reasonable basis for the
What tools does the firm deploy to uncover in-and-out trading,
high turnover rates and commission-equity ratios?
How does the firm go about determining if a client constitutes
an institutional investor for the purposes of being capable to
independently evaluate investment risks?
What protocols does the firm use to ensure that it obtains an
affirmative acknowledgement from an institutional client that it is
exercising independent judgment?
If the firm uses a portfolio analytic tool or model, how does it
determine whether the tools or models make recommendations subject
to the suitability rule or satisfy the safe harbor criteria in Rule
If you have not been subject to a FINRA suitability examination
under the new suitability rule, pose these questions to your
firm. If you cannot answer them in some fashion, you likely
do not have adequate protocols in place. Take the time to
revisit your policies and procedures before FINRA does it for
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
Now that the Final Omnibus Rule under HIPAA, originally published on January 25, 2013, is in full force, covered entities (CEs) and their continuing business associates (BAs) should be examining their existing pre-Final Omnibus Rule HIPAA Business Associate Agreements (BAAs).
Earlier this month, the U.S. Supreme Court resolved the question of whether the whistleblower protection provisions of the Sarbanes-Oxley Act of 2002 protect employees of private contractors of publicly traded companies from retaliation for reporting potential fraud.